
In a recent episode of our Molecular Imaging in Focus series, Christopher Rowe, MD, BMBS, FRACP, FAANMS, discussed pertinent phase 3 study findings for florquinitau F 18 that were presented at the recent Clinical Trials on Alzheimer’s Disease conference.







